|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
DE69218414T2
(de)
|
1991-02-27 |
1998-01-22 |
Pfizer |
Verfahren zur herstellung von trans-piperidin-2,5-dicarboxylaten
|
|
CA2192725C
(en)
|
1995-12-28 |
2004-04-20 |
Kenji Tsujihara |
Camptothecin derivatives
|
|
WO2003000657A1
(en)
|
2001-06-20 |
2003-01-03 |
Daiichi Pharmaceutical Co., Ltd. |
Diamine derivatives
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
EP1701979A2
(en)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimized antibodies that target the epidermal growth factor receptor
|
|
WO2009011285A1
(ja)
|
2007-07-13 |
2009-01-22 |
Taisho Pharmaceutical Co., Ltd. |
ヘテロアリールベンゼン化合物
|
|
MX2010011145A
(es)
|
2008-04-11 |
2011-04-11 |
Merrimack Pharmaceuticals Inc |
Enlazadores de la albumina de suero humana y conjugados de la misma.
|
|
WO2010019952A2
(en)
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
WO2010059315A1
(en)
|
2008-11-18 |
2010-05-27 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
AR076508A1
(es)
|
2009-05-01 |
2011-06-15 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2777825A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9051370B2
(en)
|
2010-08-10 |
2015-06-09 |
Glycotope Gmbh |
Humanized EGFR antibodies
|
|
UY33707A
(es)
|
2010-11-04 |
2012-05-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY33826A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión con dominios trivariables y sus usos
|
|
CN103547598A
(zh)
|
2011-02-24 |
2014-01-29 |
梅里麦克制药股份有限公司 |
包含抗-erbb3药剂的联合治疗
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
US20130195871A1
(en)
|
2011-12-30 |
2013-08-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
AU2013229786B2
(en)
|
2012-03-08 |
2017-06-22 |
Halozyme, Inc. |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
MX2014013763A
(es)
|
2012-05-11 |
2015-02-20 |
Merrimack Pharmaceuticals Inc |
Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
|
|
JP5977349B2
(ja)
|
2012-06-15 |
2016-08-24 |
田辺三菱製薬株式会社 |
芳香族複素環化合物
|
|
US9683044B2
(en)
|
2012-08-20 |
2017-06-20 |
Gliknik Inc. |
Molecules with antigen binding and polyvalent FC gamma receptor binding activity
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
US20150239977A1
(en)
|
2012-09-27 |
2015-08-27 |
Massachusetts Institute Of Technology |
Cd20- and egfr-binding proteins with enhanced stability
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
CA2902830C
(en)
|
2013-03-12 |
2023-09-19 |
Biocon Ltd. |
Fusion immunomodulatory proteins and methods for making same
|
|
JP2016514676A
(ja)
|
2013-03-15 |
2016-05-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
四価二重特異性抗体
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
AU2014371934B2
(en)
|
2013-12-25 |
2020-01-23 |
Daiichi Sankyo Company, Limited |
Anti-TROP2 antibody-drug conjugate
|
|
IL310627B2
(en)
|
2014-01-31 |
2026-04-01 |
Daiichi Sankyo Co Ltd |
Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
|
|
CA2937753A1
(en)
*
|
2014-02-17 |
2015-08-20 |
Seattle Genetics, Inc. |
Hydrophilic antibody-drug conjugates
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
EP3130608B1
(en)
*
|
2014-04-10 |
2019-09-04 |
Daiichi Sankyo Co., Ltd. |
(anti-her2 antibody)-drug conjugate
|
|
EP3154587B1
(en)
|
2014-06-13 |
2020-01-15 |
Tenboron OY |
Conjugates comprising an anti-egfr1 antibody
|
|
JP6214790B2
(ja)
|
2014-09-16 |
2017-10-18 |
イース チャーム リミテッド |
抗ｅｇｆｒ抗体および同抗体の使用法
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
CA3138083A1
(en)
|
2014-12-22 |
2016-06-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
KR101770559B1
(ko)
|
2015-04-23 |
2017-08-24 |
신일제약주식회사 |
EGFR에 특이적으로 결합하는 Fab 단편
|
|
EP3316907A4
(en)
|
2015-06-01 |
2019-02-13 |
ImmuneXcite, Inc. |
CONTAINS OF BETA-1,6-GLUCAN AND ANTIBODY CÉTUXIMAB
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US20170247458A1
(en)
|
2016-01-10 |
2017-08-31 |
Sorrento Therapeutics, Inc. |
Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
|
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
|
SG11201809316XA
(en)
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
CN116333130A
(zh)
|
2016-05-24 |
2023-06-27 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
|
WO2018026742A1
(en)
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
GB201705686D0
(en)
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CN108948206B
(zh)
|
2017-05-23 |
2022-08-23 |
赵磊 |
一种抗egfr/pd-1双靶向抗体、其制备方法及用途
|
|
CN108948195B
(zh)
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
CN110719920B
(zh)
|
2017-06-14 |
2024-01-30 |
苏州丁孚靶点生物技术有限公司 |
蛋白质异二聚体及其用途
|
|
US12605458B2
(en)
|
2017-06-19 |
2026-04-21 |
Systimmune, Inc. |
Antibody-drug conjugate having acidic self-stabilization junction
|
|
CN109306010B
(zh)
|
2017-07-26 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
表皮生长因子受体抗体及其用途
|
|
EP3668893A4
(en)
|
2017-08-16 |
2021-08-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
|
|
WO2019034176A1
(zh)
|
2017-08-18 |
2019-02-21 |
四川百利药业有限责任公司 |
一种喜树碱-抗体偶联物
|
|
IL324591A
(en)
|
2017-08-31 |
2026-01-01 |
Daiichi Sankyo Co Ltd |
Improved antibody-drug conjugate production methods
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
CN108220244A
(zh)
|
2018-01-18 |
2018-06-29 |
东北农业大学 |
一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
|
|
US10633458B2
(en)
|
2018-04-10 |
2020-04-28 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
CA3103374A1
(en)
|
2018-06-29 |
2020-01-02 |
Krystal Biotech, Inc. |
Compositions and methods for antibody delivery
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
CA3114474A1
(en)
|
2018-09-30 |
2020-04-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
JP7410143B2
(ja)
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
CN111196855B
(zh)
|
2018-11-19 |
2022-11-15 |
三生国健药业（上海）股份有限公司 |
抗egfr/pd-1双特异性抗体
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
US12344646B2
(en)
|
2018-12-13 |
2025-07-01 |
Bang DING |
Antibody-TNF α fusion protein and its preparation and applications
|
|
CN113677703A
(zh)
|
2018-12-17 |
2021-11-19 |
鳄鱼生物科学公司 |
多肽
|
|
WO2020138487A1
(ja)
|
2018-12-28 |
2020-07-02 |
協和キリン株式会社 |
ＴｆＲに結合するバイスペシフィック抗体
|
|
CN111689980A
(zh)
*
|
2019-05-26 |
2020-09-22 |
四川百利药业有限责任公司 |
一种喜树碱药物及其抗体偶联物
|
|
US20230072897A1
(en)
|
2019-06-06 |
2023-03-09 |
Shanghai Hansoh Biomedical Co., Ltd. |
Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
|
|
CN110256583B
(zh)
|
2019-07-11 |
2022-05-20 |
中国科学院生物物理研究所 |
一种il-2突变体与抗体的融合蛋白及其应用
|
|
CN114450306B
(zh)
|
2019-07-26 |
2024-04-05 |
Abl生物公司 |
抗egfr/抗4-1bb双特异性抗体及其用途
|
|
CN110669132B
(zh)
|
2019-08-19 |
2023-03-31 |
天津大学前沿技术研究院 |
一种提高IgG1抗体产量的方法
|
|
CN112125915A
(zh)
*
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
AU2020351205A1
(en)
|
2019-09-19 |
2022-04-14 |
Igm Biosciences, Inc. |
Multimeric antibodies with enhanced selectivity for cells with high target density
|
|
US20230054458A1
(en)
|
2019-12-12 |
2023-02-23 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
|
|
KR20220113747A
(ko)
|
2019-12-16 |
2022-08-16 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항 cea 항체-엑사테칸 유사체의 접합체 및 이의 약학적 용도
|
|
JP7781064B2
(ja)
|
2020-01-22 |
2025-12-05 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途
|
|
CA3168986A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
CN113388631B
(zh)
|
2020-03-12 |
2022-08-09 |
天津大学 |
一种高产IgG1的重组菌及构建方法
|
|
CN115298220B
(zh)
|
2020-03-24 |
2024-12-20 |
上海翰森生物医药科技有限公司 |
抗体-药物偶联物及其医药用途
|
|
CN115605510A
(zh)
|
2020-03-25 |
2023-01-13 |
江苏豪森药业集团有限公司（Cn） |
B7h3抗体-依喜替康类似物偶联物及其医药用途
|
|
CN115103858B
(zh)
|
2020-03-25 |
2025-07-15 |
江苏恒瑞医药股份有限公司 |
一种抗体药物偶联物的制备方法
|
|
BR112022019073A2
(pt)
|
2020-03-25 |
2022-11-08 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
|
|
MX2022011808A
(es)
|
2020-03-25 |
2022-12-06 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo.
|
|
WO2021190564A1
(zh)
|
2020-03-26 |
2021-09-30 |
上海翰森生物医药科技有限公司 |
抗体药物偶联物及其医药用途
|
|
US10994021B1
(en)
|
2020-04-11 |
2021-05-04 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Tetravalent antibody-drug conjugates and use thereof
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业（上海）股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
CN113754771A
(zh)
|
2020-06-02 |
2021-12-07 |
三生国健药业（上海）股份有限公司 |
一种抗pdl1×egfr的双特异性抗体
|
|
AU2021289927A1
(en)
*
|
2020-06-08 |
2023-01-19 |
Systimmune, Inc. |
Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
|
|
CN111848806B
(zh)
|
2020-06-18 |
2022-06-10 |
广东安普泽生物医药股份有限公司 |
Egfr-cd3双功能抗体及其应用
|
|
TWI888610B
(zh)
|
2020-07-27 |
2025-07-01 |
大陸商上海拓界生物醫藥科技有限公司 |
抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
|
|
WO2022056696A1
(zh)
|
2020-09-15 |
2022-03-24 |
四川百利药业有限责任公司 |
一种喜树碱类药物及其抗体偶联物
|
|
AU2021354827A1
(en)
|
2020-09-30 |
2023-06-01 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
|
|
US20250276078A1
(en)
*
|
2020-10-12 |
2025-09-04 |
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
Camptothecin Derivative And Ligand-drug Conjugate Thereof
|
|
JP7753372B2
(ja)
*
|
2020-10-12 |
2025-10-14 |
シーチュアン バイリ ファーム シーオー． エルティーディー |
重水素化カンプトテシン系誘導体及びその抗体薬物複合体
|
|
JP7847132B2
(ja)
|
2020-10-14 |
2026-04-16 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途
|
|
WO2022099762A1
(zh)
|
2020-11-12 |
2022-05-19 |
博瑞生物医药（苏州）股份有限公司 |
一种抗体偶联物中间体及其制备方法
|
|
CN114569739A
(zh)
|
2020-12-01 |
2022-06-03 |
正大天晴药业集团股份有限公司 |
抗体药物偶联物
|
|
EP4628165A3
(en)
|
2021-02-05 |
2026-03-11 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Camptothecin compound, preparation method therefor, and application thereof
|
|
WO2022166719A1
(zh)
|
2021-02-08 |
2022-08-11 |
四川百利药业有限责任公司 |
一种ca4衍生物及其配体-药物偶联物
|
|
CN117015549A
(zh)
|
2021-03-17 |
2023-11-07 |
江苏恒瑞医药股份有限公司 |
一种喜树碱衍生物的制备方法
|
|
CN115192732B
(zh)
|
2021-04-01 |
2025-02-18 |
成都百利多特生物药业有限责任公司 |
一种dna毒性二聚体化合物及其偶联物
|
|
TW202302649A
(zh)
|
2021-04-26 |
2023-01-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
|
|
CN113816969B
(zh)
|
2021-04-30 |
2024-01-16 |
联宁（苏州）生物制药有限公司 |
依喜替康类化合物、其抗体药物偶联物及其应用
|
|
GEAP202416409A
(en)
|
2021-05-07 |
2024-02-26 |
Alx Oncology Inc |
Exatecan derivatives and antibody-drug conjugates thereof
|
|
CN117693365A
(zh)
|
2021-06-25 |
2024-03-12 |
同宜医药（苏州）有限公司 |
配体药物偶联物及其应用
|
|
TW202320858A
(zh)
|
2021-07-19 |
2023-06-01 |
美商薩諾管理公司 |
免疫接合物及方法
|
|
CA3232425A1
(en)
|
2021-09-23 |
2023-03-30 |
Shanghai Hansoh Biomedical Co., Ltd. |
Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof
|
|
CN115850291B
(zh)
|
2021-09-24 |
2024-11-15 |
石药集团巨石生物制药有限公司 |
喜树碱衍生物及其用途
|
|
US11814394B2
(en)
|
2021-11-16 |
2023-11-14 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Exatecan derivatives, linker-payloads, and conjugates and thereof
|
|
AU2022389555A1
(en)
|
2021-11-17 |
2024-07-04 |
CSPC Megalith Biopharmaceutical Co., Ltd. |
Antibody-drug conjugate and use thereof
|
|
WO2023098889A1
(zh)
|
2021-12-03 |
2023-06-08 |
成都百利多特生物药业有限责任公司 |
抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
|
|
CA3241157A1
(en)
|
2021-12-16 |
2023-06-22 |
Wei Zhou |
Camptothecin compound and conjugate thereof
|
|
IL313805A
(en)
|
2021-12-28 |
2024-08-01 |
Beigene Switzerland Gmbh |
Drug antibody conjugates
|